JPMorgan Chase & Co. Has $24.78 Million Stock Holdings in Grifols, S.A. $GRFS

JPMorgan Chase & Co. increased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 31.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,488,294 shares of the biotechnology company’s stock after buying an additional 600,118 shares during the period. JPMorgan Chase & Co.’s holdings in Grifols were worth $24,783,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in Grifols by 39.5% during the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,584 shares during the last quarter. Peterson Wealth Services increased its stake in shares of Grifols by 385.8% during the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 5,787 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Grifols by 127.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 4,604 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Grifols by 109.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 4,518 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Grifols in the 2nd quarter valued at $95,000.

Grifols Trading Up 1.6%

Shares of Grifols stock opened at $9.10 on Monday. The company has a quick ratio of 0.88, a current ratio of 2.51 and a debt-to-equity ratio of 1.20. Grifols, S.A. has a 12-month low of $6.19 and a 12-month high of $11.14. The company has a market capitalization of $6.26 billion, a price-to-earnings ratio of 47.89, a PEG ratio of 0.32 and a beta of 0.66. The firm’s 50-day moving average price is $9.22 and its two-hundred day moving average price is $9.34.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GRFS shares. Wall Street Zen downgraded Grifols from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. lowered their target price on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Four investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.